中华内分泌代谢杂志
中華內分泌代謝雜誌
중화내분비대사잡지
CHINESE JOURNAL OF ENDOCRINOLOGY AND METABOLISM
2013年
8期
683-687
,共5页
綦一澄%李晓丽%王燕燕%章晓芳%黄凤娇%林东平%宁光%王曙
綦一澄%李曉麗%王燕燕%章曉芳%黃鳳嬌%林東平%寧光%王曙
기일징%리효려%왕연연%장효방%황봉교%림동평%저광%왕서
骨桥蛋白%Graves病%CD40配体
骨橋蛋白%Graves病%CD40配體
골교단백%Graves병%CD40배체
Osteopontin%Graves' disease%CD40 ligand
目的 探讨骨桥蛋白在Graves病(GD)中的表达情况及骨桥蛋白对CD40配体的调节作用.方法选取初发Graves病患者30例,Graves病缓解患者21例,正常志愿者20名,采用酶联免疫吸附试验(ELISA)检测患者与志愿者血浆中骨桥蛋白和可溶型CD40配体水平,运用实时荧光定量PCR检测外周血单个核细胞骨桥蛋白受体mRNA的表达和CD4+T细胞中CD40配体mRNA的表达.结果 Graves病初发患者血浆骨桥蛋白水平显著高于对照组[(153±55对52±21)ng/ml,P<0.01],而Graves病缓解患者血浆骨桥蛋白水平与对照组相比无统计学差异[(64± 19) ng/ml,P>0.05];与对照组比较,Graves病初发患者血浆可溶型CD40配体水平显著升高[(3031±1074对1073±351)pg/ml,P<0.01],Graves病缓解患者可溶型CD40配体水平与对照组比较,差异无统计学意义[(974±273) pg/ml,P>0.05];血浆骨桥蛋白与可溶型CD40配体水平呈显著正相关(r=0.849,P<0.01);人重组骨桥蛋白可促进可溶型CD40配体和CD4+T细胞中CD40配体基因mRNA的表达.结论骨桥蛋白在Graves病初发患者血浆中表达明显增加,可通过促进CD40配体的表达参与Graves病发生、发展的免疫调节过程.
目的 探討骨橋蛋白在Graves病(GD)中的錶達情況及骨橋蛋白對CD40配體的調節作用.方法選取初髮Graves病患者30例,Graves病緩解患者21例,正常誌願者20名,採用酶聯免疫吸附試驗(ELISA)檢測患者與誌願者血漿中骨橋蛋白和可溶型CD40配體水平,運用實時熒光定量PCR檢測外週血單箇覈細胞骨橋蛋白受體mRNA的錶達和CD4+T細胞中CD40配體mRNA的錶達.結果 Graves病初髮患者血漿骨橋蛋白水平顯著高于對照組[(153±55對52±21)ng/ml,P<0.01],而Graves病緩解患者血漿骨橋蛋白水平與對照組相比無統計學差異[(64± 19) ng/ml,P>0.05];與對照組比較,Graves病初髮患者血漿可溶型CD40配體水平顯著升高[(3031±1074對1073±351)pg/ml,P<0.01],Graves病緩解患者可溶型CD40配體水平與對照組比較,差異無統計學意義[(974±273) pg/ml,P>0.05];血漿骨橋蛋白與可溶型CD40配體水平呈顯著正相關(r=0.849,P<0.01);人重組骨橋蛋白可促進可溶型CD40配體和CD4+T細胞中CD40配體基因mRNA的錶達.結論骨橋蛋白在Graves病初髮患者血漿中錶達明顯增加,可通過促進CD40配體的錶達參與Graves病髮生、髮展的免疫調節過程.
목적 탐토골교단백재Graves병(GD)중적표체정황급골교단백대CD40배체적조절작용.방법선취초발Graves병환자30례,Graves병완해환자21례,정상지원자20명,채용매련면역흡부시험(ELISA)검측환자여지원자혈장중골교단백화가용형CD40배체수평,운용실시형광정량PCR검측외주혈단개핵세포골교단백수체mRNA적표체화CD4+T세포중CD40배체mRNA적표체.결과 Graves병초발환자혈장골교단백수평현저고우대조조[(153±55대52±21)ng/ml,P<0.01],이Graves병완해환자혈장골교단백수평여대조조상비무통계학차이[(64± 19) ng/ml,P>0.05];여대조조비교,Graves병초발환자혈장가용형CD40배체수평현저승고[(3031±1074대1073±351)pg/ml,P<0.01],Graves병완해환자가용형CD40배체수평여대조조비교,차이무통계학의의[(974±273) pg/ml,P>0.05];혈장골교단백여가용형CD40배체수평정현저정상관(r=0.849,P<0.01);인중조골교단백가촉진가용형CD40배체화CD4+T세포중CD40배체기인mRNA적표체.결론골교단백재Graves병초발환자혈장중표체명현증가,가통과촉진CD40배체적표체삼여Graves병발생、발전적면역조절과정.
Objective To investigate the expression of osteopontin(OPN) in Graves' disease(GD),and to study the role played by OPN in modulating CD40 ligand expression.Methods Thirty initial GD patients,twenty-one GD patients during remission,and twenty healthy controls were recruited.Concentrations of OPN and soluble CD40 ligand were determined by ELISA.The expressions of OPN receptor genes in peripheral blood mononuclear cells and CD40 ligand gene in CD4+T cell were determined by real-time quantitative PCR.Results Plasma OPN level in GD patients was significantly higher than that in normal controls[(153 ±55 vs 52±21) ng/ml,P<0.01],while the level in GD patients during remission[(64 ± 19 vs 52 ± 21) ng/ml,P>0.05] showed no significant changes.Compared to healthy controls,soluble CD40 ligand was enhanced in GD patients [(3031 ± 1074 vs 1073 ± 351) pg/ml,P<0.01]and in patients during remission,no significant differences found [(974 ± 273 vs 1073 ± 351) pg/ml,P>0.05].Plasma OPN was correlated with soluble CD40 ligand concentration(r=0.849,P<0.01),while OPN could increase soluble CD40 ligand level and CD40 ligand mRNA expression in CD4+T cells.Conclusions CD40 ligand is induced by increased OPN and serves as the downstream effector of OPN in GD development.